购物车
- 全部删除
- 您的购物车当前为空
CCG-1423 是一种选择性 RhoA 通路抑制剂,可抑制 SRF 介导的转录,能抑制细胞的转移前列腺癌PC-3细胞侵袭模型。
CCG-1423 是一种选择性 RhoA 通路抑制剂,可抑制 SRF 介导的转录,能抑制细胞的转移前列腺癌PC-3细胞侵袭模型。
规格 | 价格 | 库存 | 数量 |
---|---|---|---|
1 mg | ¥ 153 | 现货 | |
5 mg | ¥ 335 | 现货 | |
10 mg | ¥ 525 | 现货 | |
25 mg | ¥ 933 | 现货 | |
50 mg | ¥ 1,530 | 现货 | |
100 mg | ¥ 2,570 | 现货 | |
200 mg | ¥ 3,880 | 现货 | |
500 mg | ¥ 6,250 | 期货 | |
1 mL x 10 mM (in DMSO) | ¥ 375 | 现货 |
产品描述 | CCG-1423, a selective RhoA pathway inhibitor, suppresses SRF-mediated transcription. |
靶点活性 | LRRK2 (G2019S):1.85 nM, LRRK2 (WT):1.28 nM |
体内活性 | 在H9c2细胞中,CCG-1423抑制MRTF核定位,并完全阻断STARS近端报告基因活性。在人结肠肌成纤维细胞中,CCG-1423抑制TGF-β诱导的纤维增生。小鼠胚胎干细胞在CCG-1423与LY294002作用下,分化为中间中胚层。在RhoC过表达的黑色素瘤细胞(A375M2 和 SK-Mel-147)中,CCG-1423能够选择性抑制细胞增殖。 |
细胞实验 | Cells in normal culture medium are plated (2,000 per well) in a 96-well plate coated with laminin. After attachment, the medium is replaced with serum-free medium (0% FBS) with 30 μmol/L LPA with or without 300 nM CCG-1423. Fresh LPA with or without CCG-1423 is added at day 5 to ensure that LPA and compound are present throughout the experiment. On day 8, WST-1 reagent is added to the wells for 1 h and absorbance at 450 nm is read using a Victor plate reader.(Only for Reference) |
别名 | CCG1423 |
分子量 | 454.75 |
分子式 | C18H13ClF6N2O3 |
CAS No. | 285986-88-1 |
Smiles | CC(ONC(=O)c1cc(cc(c1)C(F)(F)F)C(F)(F)F)C(=O)Nc1ccc(Cl)cc1 |
密度 | no data available |
存储 | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice. | ||||||||||||||||||||||||||||||||||||||||
溶解度信息 | Ethanol: 4 mg/mL (8.79 mM), Heating is recommended. H2O: < 1 mg/mL (insoluble or slightly soluble) DMSO: 83 mg/mL (182.5 mM) | ||||||||||||||||||||||||||||||||||||||||
溶液配制表 | |||||||||||||||||||||||||||||||||||||||||
|
版权所有©2015-2024 TargetMol Chemicals Inc.保留所有权利.
评论内容